Launch of an investigator-initiated trial of VGN-R08b for treating type II Gaucher disease (GDII)
The 1st in-human trial of VGN-R08b, a gene therapy product independently developed by Shanghai Vitalgen BioPharma Co., Ltd. has been initiated in collaboration with Xinhua Hospital, affiliated with the Shanghai JiaoTong University School of Medicine. This trial will evaluate the tolerability, safety and efficacy of intracerebroventricular administration of VGN-R08b for treating GDII patients.